Our scientists and clinicians have an extensive track record of successfully working in public-private partnerships, including a partnership with the Biomedical Advanced Research and Development Authority (BARDA) that led to the first approved anti-infective drug product under that program in 2017.
Our current collaboration with BARDA is focused on advancing a portfolio of novel anti-infective products, including the xeruborbactam-based products. Funding for the development of the products in our portfolio, in whole or in part, comes from the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, BARDA, under Other Transaction Authority number HHSO100201600026C.
We also collaborate with academic institutions and private organizations that share our commitment toย developing safe and more potent anti-infectives unaffected by multidrug resistance mechanisms.